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Cardiovascular disease (CVD) remains the major cause of death 
worldwide. In modern medicine, atherosclerotic CVD and its 
ensuing complications provide a significant challenge to clinicians, 
from the level of primary care to subspecialty practice. The role of 
dyslipidaemia in the pathogenesis of atherosclerotic CVD has been 
extensively researched, and doctors across South Africa (SA) are 
often tasked with modifying this significant risk factor burden among 
a wide variety of population groups. 
When managing dyslipidaemia, it is clinically useful to separate 
hyperlipidaemia into two main categories, i.e. hypertriglyceridaemia 
and hypercholesterolaemia, particularly an increase in serum low-
density lipoprotein (LDL) cholesterol concentrations. As discussed 
in this article, even though an elevated triglyceride (TG) level may 
result in an increased risk of CVD, the greatest effect of lowering 
markedly elevated serum TG (>10 mmol/L) is the reduction in the 
risk of developing acute pancreatitis, with a reduction of serum LDL 
cholesterol being a much more powerful predictor of risk reduction 
with regard to CVD morbidity and mortality. 
Management of predominant 
hypercholesterolaemia
Statin therapy
If diet and lifestyle advice does not lower LDL cholesterol sufficiently, 
the 3-hydroxy 3-methylglutaryl co-enzyme A (HMG-CoA) reductase 
inhibitors or statins are the current mainstay of treatment of elevated 
LDL cholesterol. The most efficacious statins at their maximum dose 
can reduce LDL cholesterol by up to 50%.
Ezetimibe
Ezetimibe prevents intestinal absorption of cholesterol, and is 
currently the mainstay as a second-line agent in lowering LDL 
cholesterol. As per the European Society of Cardiology (ESC) guide-
lines, ezetimibe is recommended as an add-on therapy for patients on 
high-intensity statins, who require further LDL cholesterol reduction, 
or for patients who are statin intolerant. The IMProved Reduction of 
Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT),[1] 
which showed a 2% absolute reduction in cardiovascular events 
compared with placebo over a 6-year follow-up period in patients on 
background statin therapy, has proven the benefit of the addition of 
ezetimibe to statin therapy in reducing cardiovascular events.
While these medications have been used to excellent effect in 
lowering the rate of complications secondary to dyslipidaemia, there 
are still certain groups of the population for whom this combination 
is insufficient. The two major groups of patients who may require 
an additional or alternative approach to lipid-lowering therapy, are: 
(i) individuals with familial hypercholesterolaemia, which is highly 
prevalent in the Afrikaner, Jewish and Indian populations of SA, as 
they require a greater percentage reduction in LDL cholesterol to 
achieve acceptable LDL cholesterol target levels; and (ii) individuals 
experiencing side-effects from statin therapy, precluding the use of 
high-intensity statin therapy, i.e. statin-intolerant patients. 
New therapies for the treatment of 
hypercholesterolaemia
Proprotein convertase subtilisin/kexin type 9 inhibitor therapy
Currently riding the crest of the wave with regard to lipid-lowering 
therapy, are the therapies that inhibit the action of the proprotein 
convertase subtilisin/kexin type 9 (PCSK9) enzyme. If PCSK9 binds 
to the LDL receptor (LDL-R), mainly on the hepatocyte, instead 
of being recycled to the cell surface, the LDL-R is degraded. By 
inhibiting the function of this enzyme through the use of monoclonal 
antibodies (mAbs), the expression of LDL-R on the hepatocyte 
is increased, thereby enhancing the cellular clearance of serum 
LDL cholesterol. As of 2018, alirocumab and evolocumab, two 
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mAbs against PCSK9, i.e. PCSK9 inhibitors, which are administered 
subcutaneously every 2 - 4 weeks, have received US Food and Drug 
Administration approval as lipid-lowering agents.[2] Unfortunately, 
they have not yet been approved for clinical use in SA. These 
exciting new medications have been shown by numerous clinical 
trials to produce a significant reduction in serum LDL cholesterol 
of ~60% when used either as monotherapy or when combined 
with a statin with or without ezetimibe.[3] The recently published 
Further Cardiovascular Outcomes Research with PCSK9 Inhibition 
in Subjects with Elevated Risk (FOURIER)  trial[4] investigated 
cardiovascular outcomes in high-risk patients on background 
statin therapy, who were receiving evolocumab v. placebo and 
showed not only a significant reduction in serum LDL cholesterol 
concentration, but also a significant reduction in cardiovascular 
morbidity in those receiving the PCSK9 inhibitor. A similar study 
with alirocumab, the Evaluation of Cardiovascular Outcomes After 
an Acute Coronary Syndrome During Treatment With Alirocumab 
(ODYSSEY Outcomes),[5] has recently been completed and the results 
are eagerly awaited. A third monoclonal against PCSK9, LY3015014, 
is currently being developed. Current studies show that the reduction 
of serum LDL cholesterol concentration with the use of LY3015014 
is comparable to levels achieved by the mAbs now on the market.[5] 
The advantage of this mAb, compared with the current medication 
available, is its prolonged half-life, which enables patients to enter 
into a regimen requiring subcutaneous administration of the drug at 
4 - 8-weekly intervals, as opposed to the current mAb regimen, which 
is administered at 2 - 4-weekly intervals. 
Regarding the modulation of PCSK9 function, a fourth drug, 
inclisiran, is currently undergoing phase 3 clinical trials, and is 
showing promising results with regard to lowering serum LDL 
cholesterol concentrations.[6] As opposed to the mAbs, inclisiran 
reduces the activity of PCSK9 by inhibiting synthesis of the enzyme, 
acting at the level of protein translation via RNA interference in the 
liver. Unlike mAbs, inclisiran only needs to be administered once 
every 3 - 6 months. However, a cardiovascular outcome study with 
inclisiran will be required to prove that it has similar cardiovascular 
benefit to PCSK9 mAb therapy.
Mipomersen
A major component in the hepatic synthesis of very low-density 
lipoprotein (VLDL) and hence LDL, is the transcription and 
translation of apolipoprotein B-100 (apo B100), the carrier protein 
of LDL. A novel agent, mipomersen, which is not yet available in 
SA, inhibits the synthesis of apo B100 by ribonucleic acid (RNA) 
interference at the transcription stage. In doing so, this medication, 
classed as an antisense oligonucleotide (ASO), can reduce serum LDL 
cholesterol using an alternate pathway than the statins and PCSK9 
inhibitors. Mipomersen is administered as a weekly subcutaneous 
injection. Studies[7] with mipomersen have shown that this therapy 
can produce a significant reduction in both serum LDL cholesterol 
(25 - 39%), as well as lipoprotein (a) [Lp (a)] (21 - 39 %) when added 
to standard treatment regimens. There are some data to suggest 
that mipomersen may also result in a reduction in cardiovascular 
morbidity.[8] The largest barriers with regard to mipomersen are 
injection site reactions and the propensity for the development of 
fatty liver (hepatic steatosis), although the long-term morbidity and 
mortality with regard to hepatic disease with this agent are yet to be 
studied. 
Cholesterol ester transfer protein inhibitors 
Cholesterol ester transfer protein (CETP) is an important mediator 
protein in the lipid transport cycle owing to its ability to transfer 
cholesterol esters between lipoproteins. Inhibition of CETP results 
in a marked increase in serum high-density lipoprotein cholesterol 
(HDL cholesterol), with a reduction in serum LDL cholesterol. Three 
medications developed against CETP, i.e. torcetrapib, dalcetrapib 
and evacetrapib, have been abandoned in the trial stage owing to 
either adverse events or lack of cardiovascular benefit, with only 
anacetrapib still undergoing further evaluation. The recently reported 
Randomized Evaluation of the Effects of Anacetrapib through Lipid 
Modification (REVEAL)[9] trial showed a modest reduction in 
cardiovascular events, but the reduction was proportional to the 
reduction in LDL cholesterol and not related to the marked increase 
in HDL cholesterol observed with anacetrapib. It is therefore unlikely 
that CETP inhibitors will undergo further clinical development. 
Table 1. Novel approaches to lipid lowering
Class Drug LDL-C Triglycerides HDL-C 
HMG-CoA reductase inhibitors (statins) Atorvastatin, fluvastatin, lovastatin, 
pravastatin, rosuvastatin, simvastatin, 
pitavastatin* 
  
PPAR alpha modulators Fibrates: bezafibrate, gemfibrozil, 
fenofibrate, pemafibrate*
  
Cholesterol absorption inhibitors Ezetimibe 
PCSK9 inhibitors Alirocumab, evolocumab, LY3015014 
(mAbs),* inclisiran (reduced synthesis)*

Apo B100 inhibitors Mipomersen* 




Apo C3 inhibitors Volanesorsen*  
Lp (a) inhibitors IONIS-APO(a)Rx*
DGAT1 inhibitors Pradigastat* 
Triphosphate citrate lyase inhibitors Bempedoic acid*  
LDL-C = low-density lipoprotein cholesterol; HDL-C = high-density lipoprotein cholesterol; HMG-CoA = 3-hydroxy-3-methyl-glutaryl co-enzyme A; PPAR = protein peroxisome proliferator 
activated receptor alpha; PCSK9 = proprotein convertase subtilisin/kexin type 9; apo B100 = apolipoprotein B100; CETP = cholesterol ester transfer protein; ANGPTL3 = angiopoietin-like 
protein 3; apo C3 = apolipoprotein C3; Lp (a) = lipoprotein (a); DGAT1= diacylglycerol acetyltransferase 1; mAbs = monoclonal antibodies.
*Not available in South Africa or still undergoing clinical development.
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Management of predominant 
hypertriglyceridaemia
Dietary change and weight loss in patients who are overweight or 
obese can effectively reduce serum TG levels. However, if diet and 
lifestyle do not lower TG levels sufficiently, drug therapy may be 
required.
Statins can modestly reduce serum TG levels and are the 
agents of choice for mild hypertriglyceridaemia (TG <5 mmol/L), 
particularly if the LDL cholesterol is also elevated. However, when 
TG levels are markedly elevated, particularly if >10 mmol/L, there 
is a risk of developing acute pancreatitis, which is potentially life 
threatening. In such cases, additional or alternative TG-lowering 
therapies may be required. The major classes of drugs used for 
the treatment of hypertriglyceridaemia are the fibrates and niacin 
(nicotinic acid). However, niacin has been withdrawn in many 
countries globally, including SA, because of side-effects or lack of 
cardio vascular benefit.
Fibrates and pemafibrate
Fibrinic acid derivatives, or fibrates, are currently available in SA as 
first-line treatment for patients with severe hypertriglyceridaemia. 
These agents are agonists of the nuclear protein peroxisome 
proliferator activated receptor alpha (PPAR alpha) and therefore 
stimulate the synthesis of HDL and the activity of lipoprotein lipase, 
resulting in the increased hydrolysis of TGs, as well as a reduction 
in synthesis of apo C3. These agents are an important therapy for 
the prevention of acute pancreatitis and its clinical complications in 
patients with severe hypertriglyceridaemia (>10 mmol/L). Currently, 
there are no robust outcome studies that have demonstrated a 
definitive reduction in CVD morbidity and mortality with fibrate 
therapy. However, a reduction in CVD events was noted in a subgroup 
analysis of patients with high TG levels and low HDL cholesterol.[10] 
Fibrates, particularly fenofibrate and bezafibrate, are well tolerated 
and can be used in combination with statin therapy in patients 
requiring a reduction in both serum LDL cholesterol and TG levels. 
Pemafibrate is a new drug to the fibrate class and reveals a greater 
selectivity and activity of the PPAR alpha protein. This agent has 
been shown to produce a significant reduction in serum TG levels 
and is currently under investigation for its cardiovascular benefit 
in a large outcome study, the Pemafibrate to Reduce Cardiovascular 
OutcoMes by Reducing Triglycerides IN patiENts With diabeTes 
(PROMINENT),[11] which is enrolling patients with a combination of 
a high serum TG and low HDL cholesterol. If significant results are 
obtained, pemafibrate may be an interesting alternative to currently 
available fibrate therapy. 
Angiopoietin-like protein 3 inhibitors
Other medications belonging to the classes of antisense oligonucleo-
tides are those that inhibit the production of the angiopoietin-like 
protein 3 (ANGPTL3) enzyme. The enzyme, ANGPTL3, has been 
shown to inhibit lipoprotein lipase (LPL) and hence its modulation 
results in a reduction of serum TG. An interesting finding is that the 
inhibition of ANGPTL3 not only results in the reduction of serum 
TG, as expected, by reduction of LPL activity, but also in a reduction 
of serum LDL cholesterol.[12] The mechanism by which this reduction 
of serum LDL cholesterol is achieved is unknown. A second approach 
with regard to the inhibition of ANGPTL3 is the development of a 
monoclonal antibody against the enzyme. This mAb, evinacumab, has 
been shown to reduce TGs, LDL cholesterol and Lp (a) and is therefore 
an exciting new avenue for further exploration in the quest to lower 
lipids and improve cardiovascular outcomes. 
Apo C3 inhibitors 
Two recently published studies have shown the powerful TG-lowering 
effect that can be produced by the inhibition of apo C3. These 
studies, i.e. a Study of Volanesorsen (formerly IONIS-APOCIIIRx) in 
Patients With Familial Chylomicronemia Syndrome (APPROACH) 
and the Cardiovascular Outcomes for People Using Anticoagulation 
Strategies (COMPASS) trial,[13] have shown a serum TG reduction 
of up to 50% with the use of volanesorsen, an apo C3 inhibitor, 
when used as monotherapy in the management of dyslipidaemia. 
By inhibiting the apo C3 gene, there is both enhanced activity of 
LPL, resulting in an increased TG clearance, as well as a reduction 
in the synthesis of VLDL. The major limiting factor with the use of 
volanesorsen was the side-effects related to its use, i.e. severe injection 
site reactions and thrombocytopenia. Further studies investigating 
the clinical benefit of these medications against the side-effect profile 
are yet to be conducted.
Lipoprotein (a) inhibitors 
Lp (a), a particle with structural similarity to plasminogen, has been 
shown to be an independent risk factor for CVD, as well as for 
the development of aortic stenosis. This is probably because Lp (a) is 
an LDL-like particle, but it is also thought to inhibit the action of 
plasminogen, resulting in a reduction in fibrinolysis; hence, it is both 
proatherogenic and prothrombotic. An antisense oligonucleotide, 
IONIS-APO(a)Rx, is currently undergoing clinical trials, with 
preliminary results showing a significant reduction in Lp (a) levels with 
the use of this treatment.[14] The use of this medication in lowering 
Lp (a) and subsequent CVD is yet to be determined, but it provides 
an interesting alternate pathway in lowering cardiovascular mortality 
in patients requiring Lp (a) reduction therapy. 
Other novel therapies on the horizon
Pradigastat is an oral inhibitor of the enzyme diacylglycerol acyl-
transferase 1 (DGAT1), which prevents fat absorption in the small 
intestine, as well as TG synthesis. This drug is currently undergoing 
large-scale clinical trials, with small studies revealing a serum TG 
reduction of up to 70%.[15]
Bempedoic acid (ETC-1002) is currently undergoing phase 2 
clinical trials, with early results showing a significant reduction in LDL 
cholesterol, 30% as monotherapy and 50% when added to ezetimibe.[16] 
This drug inhibits the enzyme adenosine triphosphate citrate lyase, 
which results in a decreased production of both cholesterol and TGs. 
In newer studies, the role of modulation of the receptor asialo-
glycoprotein receptor 1 (ASGR1) is being explored. Individuals with 
a genetic variant of ASGR1 have been shown to have a lower LDL 
cholesterol, lower TG and higher HDL cholesterol concentrations. 
Based on this finding, it may be of interest to explore this receptor, 
and hence the modulation of its function, to produce a favourable 
outcome in patients with dyslipidaemia. 
Conclusion
Treatment modalities in the management of dyslipidaemia and the 
complications thereof are making tremendous leaps forward as 
medical technology advances. These new and novel approaches are 
now widening the net for individuals who require a greater reduction 
in serum lipid concentrations, and are also showing promise in 
patients who were previously unable to partake in first-line therapies 
owing to side-effects. The end goal that will hopefully be achieved 
with these exciting new strategies is to lower patients’ risk profile, 
while improving compliance by enhancing dose scheduling and 
reducing the side-effect profile of these treatments. It is our hope 
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that the thirst for knowledge in combating dyslipidaemia will lead to 
a continued push toward technological advancement in this exciting 
field of medicine. 
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